Literature DB >> 21560201

Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4.

Marta Dabek1, Laurent Ferrier, Anita Annahazi, Valérie Bézirard, Arnaud Polizzi, Christel Cartier, Mathilde Leveque, R Roka, Tibor Wittmann, Vassilia Theodorou, Lionel Bueno.   

Abstract

BACKGROUND: Cathepsin G (Cat-G) is a neutrophil serine-protease found in the colonic lumen of ulcerative colitis (UC) patients. Cat-G is able to activate protease-activated receptor-4 (PAR(4) ) located at the apical side of enterocytes, leading to epithelial barrier disruption. However, the mechanisms through which Cat-G triggers inflammation are not fully elucidated. The aims of our study were to evaluate in vivo the effects of UC fecal supernatants and Cat-G on epithelial barrier function and inflammation, and the connection between these two parameters.
METHODS: Male balb/c mice were used in this study. We evaluated the effect of a 2-hour intracolonic infusion of 1) fecal supernatants from UC patients pretreated or not with specific Cat-G inhibitor (SCGI); 2) PAR(4) -activating peptide (PAR(4) -AP); and 3) Cat-G on colonic myeloperoxidase (MPO) activity and paracellular permeability (CPP). The involvement of PAR(4) was assessed by pretreating animals with pepducin P4pal-10, which blocks PAR(4) signaling. We investigated the role of myosin light chain (MLC) kinase by using its inhibitor, ML-7, and we determined phosphorylated MLC (pMLC) levels in mice colonic mucosa.
RESULTS: UC fecal supernatants, Cat-G, and PAR(4) agonist increased both CPP and MPO activity in comparison with healthy subjects fecal supernatants. ML-7 inhibited the CPP increase triggered by Cat-G by 92.3%, and the enhanced MPO activity by 43.8%. Intracolonic infusion of UC fecal supernatant determined an increased phosphorylation level of MLC.
CONCLUSIONS: These observations support that luminal factors such as Cat-G play an important proinflammatory role in the pathogenesis of colitis, mainly depending on CPP increase by MLC phosphorylation.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21560201     DOI: 10.1002/ibd.21454

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction.

Authors:  Shi-Yi Zhou; Merritt Gillilland; Xiaoyin Wu; Pornchai Leelasinjaroen; Guanpo Zhang; Hui Zhou; Bo Ye; Yuanxu Lu; Chung Owyang
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

Review 2.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 3.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

4.  Enterococcus faecalis Gelatinase Mediates Intestinal Permeability via Protease-Activated Receptor 2.

Authors:  Nitsan Maharshak; Eun Young Huh; Chorlada Paiboonrungruang; Michael Shanahan; Lance Thurlow; Jeremy Herzog; Zorka Djukic; Roy Orlando; Rafal Pawlinski; Melissa Ellermann; Luke Borst; Siten Patel; Iris Dotan; Ryan B Sartor; Ian M Carroll
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

5.  Chymase-mediated intestinal epithelial permeability is regulated by a protease-activating receptor/matrix metalloproteinase-2-dependent mechanism.

Authors:  Katherine R Groschwitz; David Wu; Heather Osterfeld; Richard Ahrens; Simon P Hogan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-01-10       Impact factor: 4.052

Review 6.  Protease-activated receptor 4: from structure to function and back again.

Authors:  Shauna L French; Justin R Hamilton
Journal:  Br J Pharmacol       Date:  2016-03-10       Impact factor: 8.739

Review 7.  Protease-Activated Receptors in the Intestine: Focus on Inflammation and Cancer.

Authors:  Morgane Sébert; Nuria Sola-Tapias; Emmanuel Mas; Frédérick Barreau; Audrey Ferrand
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-24       Impact factor: 5.555

Review 8.  Gut Serpinome: Emerging Evidence in IBD.

Authors:  Héla Mkaouar; Vincent Mariaule; Soufien Rhimi; Juan Hernandez; Aicha Kriaa; Amin Jablaoui; Nizar Akermi; Emmanuelle Maguin; Adam Lesner; Brice Korkmaz; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model.

Authors:  Hanne Van Spaendonk; Hannah Ceuleers; Annemieke Smet; Maya Berg; Jurgen Joossens; Pieter Van der Veken; Sven M Francque; Anne-Marie Lambeir; Joris G De Man; Ingrid De Meester; Koen Augustyns; Benedicte Y De Winter
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

Review 10.  Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation.

Authors:  Huiyun Zhang; Xiaoning Zeng; Shaoheng He
Journal:  Mediators Inflamm       Date:  2014-04-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.